A power struggle over Nexperia, a Chinese-owned Dutch semiconductor maker, is impacting global auto production. The Dutch government has taken control of Nexperia, citing national security concerns. This move highlights vulnerabilities in the technology supply chain, affecting automakers like Honda, which halted production at a Mexican factory. The dispute is part of a broader U.S.-China tech rivalry, with Europe caught in the middle. Recent talks between the Dutch and Chinese governments show signs of resolving the crisis.
Modern automobiles rely on so-called discrete chips made by companies like Nexperia, which, unlike more advanced microprocessors, perform a single function. Leaders at big carmakers spelled out their worries in the latest round of earnings calls, saying that finding a replacement for Nexperia at scale in the short term will be difficult.
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral and injectable treatments for obesity and diabetes. On Friday, Metsera announced that Pfizer will acquire the company for up to $86.25 per share, including cash and contingent value rights. Metsera’s board said it believes this deal offers the best value and certainty for shareholders. Novo Nordisk, which had increased its offer to $10 billion, announced on Saturday that it would not continue pursuing the acquisition.
Want more insights? Join Grow With Caliber - our career elevating newsletter and get our take on the future of work delivered weekly.
